Thrombosis and Haemostasis 2018 Editor's Choice Papers

While looking ahead to a brand New Year, we also would like to invite you to look back at some of the successful articles and ‘hot topics’ we were honoured to publish in 2018. Far from attempting to give an exhaustive overview of all valuable manuscripts we were delighted to publish last year, we focus here on those which had most resonance among our reader community, either because of the novelty of their findings or their usefulness and clinical applicability.

• References

• 1 Kojima M, Ozawa N, Mori Y. , et al. Catestatin prevents macrophage-driven atherosclerosis but not arterial injury-induced neointimal hyperplasia. Thromb Haemost 2018; 118 (01) 182-194
• 2 Ebrahim M, Jamasbi J, Adler K. , et al. Dimeric glycoprotein VI binds to collagen but not to fibrin. Thromb Haemost 2018; 118 (02) 351-361
• 3 Miller L, Weissmüller S, Ringler E. , et al; ABIRISK consortium. Danger signal-dependent activation of human dendritic cells by plasma-derived factor VIII products. Thromb Haemost 2015; 114 (02) 268-276
• 4 Miller L, Ringler E, Kistner KM, Waibler Z. ; ABIRISK Consortium. Human dendritic cells synergistically activated by FVIII plus LPS induce activation of autologous CD4+ T cells. Thromb Haemost 2018; 118 (04) 688-699
• 5 Claes J, Ditkowski B, Liesenborghs L. , et al. Assessment of the dual role of clumping factor A in S. aureus adhesion to endothelium in absence and presence of plasma. Thromb Haemost 2018; 118 (07) 1230-1241
• 6 Döring Y, Noels H, van der Vorst EPC. , et al. Vascular CXCR4 limits atherosclerosis by maintaining arterial integrity: evidence from mouse and human studies. Circulation 2017; 136 (04) 388-403
• 7 Merckelbach S, van der Vorst EPC, Kallmayer M. , et al. Expression and cellular localization of CXCR4 and CXCL12 in human carotid atherosclerotic plaques. Thromb Haemost 2018; 118 (01) 195-206
• 8 Wang X, Pan B, Hashimoto Y. , et al. Defibrotide stimulates angiogenesis and protects endothelial cells from calcineurin inhibitor-induced apoptosis via upregulation of AKT/Bcl-xL. Thromb Haemost 2018; 118 (01) 161-173
• 9 Gosselin RC, Adcock DM, Bates SM. , et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2018; 118 (03) 437-450
• 10 Chao TF, Lip GYH, Lin YJ. , et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost 2018; 118 (04) 768-777
• 11 Blondon M, Spirk D, Kucher N. , et al. Comparative performance of clinical risk assessment models for hospital-acquired venous thromboembolism in medical patients. Thromb Haemost 2018; 118 (01) 82-89
• 12 Ariza-Solé A, Guerrero C, Formiga F. , et al; On Behalf of the LONGEVO-SCA Registry Investigators. Global geriatric assessment and in-hospital bleeding risk in elderly patients with acute coronary syndromes: insights from the LONGEVO-SCA Registry. Thromb Haemost 2018; 118 (03) 581-590
• 13 Garay A, Ariza-Solé A, Formiga F. , et al. Prediction of post-discharge bleeding in elderly patients with acute coronary syndromes: insights from the BleeMACS Registry. Thromb Haemost 2018; 118 (05) 929-938
• 14 Capodanno D, Greco A. Risk stratification for bleeding in the elderly with acute coronary syndrome: not so simple. Thromb Haemost 2018; 118 (06) 949-952
• 15 Borre ED, Goode A, Raitz G. , et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost 2018; 118 (12) 2171-2187
• 16 Proietti M, Mujovic N, Potpara TS. Optimizing stroke and bleeding risk assessment in patients with atrial fibrillation: a balance of evidence, practicality and precision. Thromb Haemost 2018; 118 (12) 2014-2017
• 17 Hohnloser SH, Basic E, Hohmann C, Nabauer M. Effectiveness and safety of non-vitamin K oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. Thromb Haemost 2018; 118 (03) 526-538
• 18 Potpara TS. Comparing non-vitamin K antagonist oral anticoagulants (NOACs) to different coumadins: the win-win scenarios. Thromb Haemost 2018; 118 (05) 803-805
• 19 Bikdeli B, Jimenez D, Hawkins M. , et al; RIETE Investigators. Rationale, design and methodology of the computerized registry of patients with venous thromboembolism (RIETE). Thromb Haemost 2018; 118 (01) 214-224
• 20 Grandone E, Di Micco PP, Villani M. , et al; RIETE Investigators. Venous thromboembolism in women undergoing assisted reproductive technologies: data from the RIETE Registry. Thromb Haemost 2018; 118 (11) 1962-1968
• 21 Piazza G. Oh heavy burden: recognizing the risk of venous thromboembolism in women undergoing assisted reproduction. Thromb Haemost 2018; 118 (12) 2011-2013
• 22 Galanaud JP, Bertoletti L, Amitrano M. , et al; RIETE registry investigators. Predictors of post-thrombotic ulcer after acute DVT: the RIETE Registry. Thromb Haemost 2018; 118 (02) 320-328
• 23 Frere C, Trujillo-Santos J, Font C. , et al; RIETE Investigators. Clinical course of venous thromboembolism in patients with pancreatic cancer: insights from the RIETE Registry. Thromb Haemost 2018; 118 (06) 1119-1122
• 24 Esteve-Pastor MA, Rivera-Caravaca JM, Roldán-Rabadán I. , et al; FANTASIIA Study Investigators. Relation of renal dysfunction to quality of anticoagulation control in patients with atrial fibrillation: the FANTASIIA Registry. Thromb Haemost 2018; 118 (02) 279-287
• 25 Farag M, Spinthakis N, Srinivasan M, Sullivan K, Wellsted D, Gorog DA. Morphine analgesia pre-PPCI is associated with prothrombotic state, reduced spontaneous reperfusion and greater infarct size. Thromb Haemost 2018; 118 (03) 601-612
• 26 Ibrahim K, Shah R, Goli RR. , et al. Fentanyl delays the platelet inhibition effects of oral ticagrelor: full report of the PACIFY randomized clinical trial. Thromb Haemost 2018; 118 (08) 1409-1418
• 27 Duerschmied D, Bode C. Life-saving therapy versus symptom relief: anti-platelet agents and opioids in coronary intervention. Thromb Haemost 2018; 118 (08) 1350-1351
• 28 Kraaijpoel N, Di Nisio M, Mulder FI. , et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study. Thromb Haemost 2018; 118 (08) 1439-1449
• 29 Kraaijpoel N, van Es N, Raskob GE. , et al. Risk scores for occult cancer in patients with venous thromboembolism: a post hoc analysis of the Hokusai-VTE Study. Thromb Haemost 2018; 118 (07) 1270-1278
• 30 Potpara TS, Poposka L. The challenge of thromboprophylaxis in cancer patients-balancing the thrombotic and bleeding risks. Thromb Haemost 2018; 118 (08) 1347-1349
• 31 Jiménez D, Bikdeli B. Scores to identify occult cancer in venous thromboembolism: do they work?. Thromb Haemost 2018; 118 (08) 1343-1344
• 32 Bauersachs R, Lee AYY, Kamphuisen PW. , et al; CATCH Investigators. Renal impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism-analysis of the CATCH Study. Thromb Haemost 2018; 118 (05) 914-921
• 33 Agnelli G, Becattini C, Bauersachs R. , et al; Caravaggio Study Investigators. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio Study. Thromb Haemost 2018; 118 (09) 1668-1678
• 34 Pelland-Marcotte MC, Pole JD, Kulkarni K. , et al. Thromboembolism incidence and risk factors in children with cancer: a population-based cohort study. Thromb Haemost 2018; 118 (09) 1646-1655
• 35 Grilz E, Posch F, Königsbrügge O. , et al. Association of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with the risk of thromboembolism and mortality in patients with cancer. Thromb Haemost 2018; 118 (11) 1875-1884
• 36 Campello E, Henderson MW, Noubouossie DF, Simioni P, Key NS. Contact system activation and cancer: new insights in the pathophysiology of cancer-associated thrombosis. Thromb Haemost 2018; 118 (02) 251-265
• 37 Kraaijpoel N, van Es N, Bleker SM. , et al. Clinical impact and course of anticoagulant-related major bleeding in cancer patients. Thromb Haemost 2018; 118 (01) 174-181
• 38 Aharon A, Sabbah AR, Issman L. , et al. Effects of low- and high-dose chemotherapy agents on thrombogenic properties of extracellular vesicles derived from breast cancer cell lines. Thromb Haemost 2018; 118 (03) 480-489
• 39 Douketis JD, Murphy SA, Antman EM. , et al. Peri-operative adverse outcomes in patients with atrial fibrillation taking warfarin or edoxaban: analysis of the ENGAGE AF-TIMI 48 Trial. Thromb Haemost 2018; 118 (06) 1001-1008
• 40 Proietti M, Lane DA. Use of NOACs in the peri-operative management of patients with atrial fibrillation: to stop, bridge or continue?. Thromb Haemost 2018; 118 (07) 1123-1126